News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Related Content
Trending on PharmExec
1
Pharmaceutical Executive Daily: Unpacking IRA-Driven Formulary Pressure
2
President Trump Set to Nominate Heidi Overton as FDA Commissioner
3
When Drug Pricing Becomes Trade Policy
4
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
5